You've decided LUPKYNIS® is right for your patient– Aurinia Alliance® is here to help

Lupkynis® (voclosporin) capsules 7.9 mg

Once you've prescribed LUPKYNIS, Aurinia Alliance offers assistance in a variety of ways

Aurinia Alliance provides a suite of services:

Patients' personal Nurse Case Managers

Trained specifically for lupus nephritis (LN), our bilingual Nurse Case Managers can answer questions your patients have about their medication or the process.

Dedicated specialty pharmacy partners

PharmaCord will transfer your prescription to either of our partner pharmacies, Biologics by McKesson or PANTHERx Rare Pharmacy. By utilizing this network, we are able to automatically apply financial assistance.

E-prescribe for a fast start

Get your patient started quickly on LUPKYNIS. No start form needed to digitally prescribe through PharmaCord (NABP 1836191).

Confirmed access within 5 days

Most patients have confirmed access to LUPKYNIS within 5 days from the prescription being received.

$0 or low out-of-pocket cost

97% of the time, patients paid less than $10 for LUPKYNIS. 90% of the time, patients paid $0.*

85% adherence rate

During an 18-month assessment, most patients remained on therapy, with an overall 85% adherence rate.†

Our partner specialty pharmacies can submit the prior authorization for you, when allowed by the payer.

*Since January 2021. Includes patients with Commercial, Medicaid, or Medicare.
†Data were calculated from January 2021 through June 2022. Patients were on LUPKYNIS for at least 90 days. Includes bridge, commercial, Medicare, and Medicaid covered patients.

Indications

LUPKYNIS is indicated in combination with a background immunosuppressive therapy regimen for the treatment of adult patients with active lupus nephritis (LN). Limitations of Use: Safety and efficacy of LUPKYNIS have not been established in combination with cyclophosphamide. Use of LUPKYNIS is not recommended in this situation.

Important Safety Information

BOXED WARNINGS: MALIGNANCIES AND SERIOUS INFECTIONS

Increased risk for developing malignancies and serious infections with LUPKYNIS or other immunosuppressants that may lead to hospitalization or death.

Please see additional Important Safety Information on the following pages and accompanying Prescribing Information including Boxed Warning and Medication Guide for LUPKYNIS in pocket.

Aurinia Alliance™

Now that you have prescribed LUPKYNIS, you may have some additional questions. Please review our FAQs.

I'm concerned about the cost of LUPKYNIS for my patients.

97% of the time, patients paid less than $10 for LUPKYNIS. By providing consent, eligible patients will have automatic savings applied. Their Nurse Case Manager can help explain all cost savings and access options available to them.

What if my patient's insurance does not cover LUPKYNIS right away?

Eligible* patients experiencing a delay in coverage may receive LUPKYNIS at no cost to them through our Bridge Program.

What if my patients don't have insurance or are unable to obtain coverage?

Eligible* patients may be able to obtain LUPKYNIS at no cost to them through our patient assistance program.

I'd like to reduce the time my office spends on prior authorizations and related paperwork.

The specialty pharmacies that distribute LUPKYNIS can complete and submit the prior authorization and first-level appeal when permitted by the payer.

Can I use my own specialty pharmacy?

We have intentionally partnered with 2 specialty pharmacies that understand LN patients' needs. They can help with your patient's enrollment into the Aurinia Alliance program to assist them with adherence and financial assistance. LUPKYNIS will need to be distributed by our partner pharmacies; however, a Field Access Navigator can help to incorporate your pharmacy into the process.

Do I need to submit a start form for my patient?

If you e-prescribe and select PharmaCord as the specialty pharmacy option, no start form is needed. If you chose not to e-prescribe, a start form will be required.

PharmaCord contact info:
11001 Bluegrass Parkway,
Suite 200
Louisville, KY 40299
NPI: 1699202838
NABP: 1836191

Fax or e-prescribe your prescription. To expedite your patient's access, please submit all clinical notes, documentation, and labs.

http://www.lupkynispro.com/starting-patients

Scan this QR code to get the Start Form:

*To be eligible for the Bridge program, patients must:
- Have an on-label diagnosis (ie, M32.14 diagnosis code for lupus nephritis)
- Be treated by a licensed US healthcare provider
- Have given consent to Aurinia Alliance
- Be a US resident for 6 months or more with a valid US mailing address
- Be commercially or federally insured
  - Note that government-insured patients are subject to a 5-business day waiting period following a completed payer submission (eg, prior authorization, formulary exception, or new-to-market exception)

Prescribers must:
- Submit a Bridge prescription, via the Patient Start Form, Aurinia Alliance Bridge Rx Form, e-prescription, or state-mandated prescription medium.
- Be actively pursuing insurance coverage

Important Safety Information (cont.)

CONTRAINDICATIONS: LUPKYNIS is contraindicated in patients taking strong CYP3A4 inhibitors because of the increased risk of acute and/or chronic nephrotoxicity, and in patients who have had a serious/severe hypersensitivity reaction to LUPKYNIS or its excipients.

WARNINGS AND PRECAUTIONS

Lymphoma and Other Malignancies: Immunosuppressants, including LUPKYNIS, increase the risk of developing lymphomas and other malignancies, particularly of the skin. The risk appears to be related to increasing doses and duration of immunosuppression rather than to the use of any specific agent.

Please see additional Important Safety Information on the other pages and accompanying Prescribing Information including Boxed Warning and Medication Guide for LUPKYNIS in pocket.

My patients may need support with coverage or clinical questions.

Nurse Care Managers reach out to patients upon receipt of the prescription and will answer clinical questions. **They can help discuss financial options with patients, provide an overview of the process, and make monthly adherence calls.**

My office uses CoverMyMeds. Can it help me with LUPKYNIS?

If you choose to submit your own prior authorizations, CoverMyMeds is a quick and easy option. Since Aurinia is partnered with CoverMyMeds, **we will be able to assist and track the approval process** alongside your office. Prescriptions will need to be sent to PharmaCord.

How quickly can we get patients started on LUPKYNIS?

Most patients are approved with a prior authorization. To expedite the process, it is important to submit the prescription along with all documentation, clinical notes, and labs. Our pharmacies can **submit a prior authorization in as little as 24 hours** if they have all the required information and if allowed by the payer.

Patient consent is required to access Aurinia Alliance programs. How can I help my patient provide it?

There are a few ways for your patients to consent:

1. They can sign the start form when they are in the office.
2. Your patient can verbally consent when they call, or take a call from their Nurse Case Manager.
3. Use DocuSign via auriniaalliance.com.



Questions or concerns? Your Field Access Navigator is here to answer any questions you have about the program.

With a complete prescription and clinical notes, patient consent prior authorizations can be submitted as quickly as 24 hours after receipt

Have more questions? We are ready to help

Call 1-833-AURINIA (1-833-287-4642) 8AM to 8PM EST

or email support@AuriniaAlliance.com

Important Safety Information (cont.)

WARNINGS AND PRECAUTIONS (cont.)

Serious Infections: Immunosuppressants, including LUPKYNIS, increase the risk of developing bacterial, viral, fungal, and protozoal infections (including opportunistic infections), which may lead to serious, including fatal, outcomes.

Nephrotoxicity: LUPKYNIS, like other calcineurin inhibitors (CNIs), may cause acute and/or chronic nephrotoxicity. The risk is increased when CNIs are concomitantly administered with drugs associated with nephrotoxicity.

Hypertension: Hypertension is a common adverse reaction of LUPKYNIS therapy and may require antihypertensive therapy.

Please see additional Important Safety Information on the other pages and accompanying Prescribing Information including Boxed Warning and Medication Guide for LUPKYNIS in pocket.

Aurinia Alliance™

Lupkynis® (voclosporin) capsules 7.9 mg

Want in-person support? We'll drop by.

To request a rep visit, scan this QR code or visit:

https://lupkynispro.com/get-connected/

Important Safety Information (cont.)

WARNINGS AND PRECAUTIONS (cont.)

Neurotoxicity: LUPKYNIS, like other CNIs, may cause a spectrum of neurotoxicities: severe include posterior reversible encephalopathy syndrome (PRES), delirium, seizure, and coma; others include tremor, paresthesia, headache, and changes in mental status and/or motor and sensory functions.

Hyperkalemia: Hyperkalemia, which may be serious and require treatment, has been reported with CNIs, including LUPKYNIS. Concomitant use of agents associated with hyperkalemia may increase the risk for hyperkalemia.

QTc Prolongation: LUPKYNIS prolongs the QTc interval in a dose-dependent manner when dosed higher than the recommended lupus nephritis therapeutic dose. The use of LUPKYNIS in combination with other drugs that are known to prolong QTc may result in clinically significant QT prolongation.

Immunizations: Avoid the use of live attenuated vaccines during treatment with LUPKYNIS. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment with LUPKYNIS.

Pure Red Cell Aplasia: Cases of pure red cell aplasia (PRCA) have been reported in patients treated with another CNI immunosuppressant. If PRCA is diagnosed, consider discontinuation of LUPKYNIS.

Drug-Drug Interactions: Avoid co-administration of LUPKYNIS and strong CYP3A4 inhibitors or with strong or moderate CYP3A4 inducers. Reduce LUPKYNIS dosage when co-administered with moderate CYP3A4 inhibitors. Reduce dosage of certain P-gp substrates with narrow therapeutic windows when co-administered.

ADVERSE REACTIONS

The most common adverse reactions (≥3%) were glomerular filtration rate decreased, hypertension, diarrhea, headache, anemia, cough, urinary tract infection, abdominal pain upper, dyspepsia, alopecia, renal impairment, abdominal pain, mouth ulceration, fatigue, tremor, acute kidney injury, and decreased appetite.

SPECIFIC POPULATIONS

Pregnancy/Lactation: May cause fetal harm. Advise not to breastfeed. Renal Impairment: Not recommended in patients with baseline eGFR ≤45 mL/min/1.73 m2 unless benefit exceeds risk. If used in this population, reduce LUPKYNIS dose.

Hepatic Impairment: For mild or moderate hepatic impairment, reduce LUPKYNIS dose. Avoid use with severe hepatic impairment.

Please see accompanying Prescribing Information including Boxed Warning and Medication Guide for LUPKYNIS in pocket.

All trademarks and associated logos are the property of Aurinia Pharmaceuticals Inc.
©2023 Aurinia Pharma U.S., Inc. All rights reserved. 3/23
US-LUP-2300071

Aurinia Alliance™

Lupkynis® (voclosporin) capsules 7.9 mg